PTC Therapeutics, Inc (PTCT) insider trading
Every open-market stock purchase and sale by PTC Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Michael Schmertzler (Insider) and 3 others sold $8.5M in the last 90 days.
- Last insider buy: Pierre Gravier (CFO), $199K, 2 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $56.5M (70 sales). Last close $62.62 on Oct 21, 2026.
Recent PTCT insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Oct 14, 2026 | Michael Schmertzler (Insider) | Sold | $126K |
| Oct 14, 2026 | Michael Schmertzler (Insider) | Sold | $23K |
| Oct 9, 2026 | Mark Elliott Boulding (C-suite exec) | Sold | $12.3K |
| Oct 9, 2026 | Mark Elliott Boulding (C-suite exec) | Bought (not open market) | $7.6K |
| Oct 9, 2026 | Mark Elliott Boulding (C-suite exec) | Bought (not open market) | — |
| Oct 7, 2026 | Michael Schmertzler (Insider) | Sold | $155K |
| Oct 7, 2026 | Michael Schmertzler (Insider) | Sold | $3.4K |
| Oct 6, 2026 | Mark Elliott Boulding (C-suite exec) | Sold | $27.9K |
| Oct 6, 2026 | Mark Elliott Boulding (C-suite exec) | Bought (not open market) | — |
| Oct 5, 2026 | Mark Elliott Boulding (C-suite exec) | Sold | $105K |
| Oct 5, 2026 | Mark Elliott Boulding (C-suite exec) | Bought (not open market) | — |
| Sep 30, 2026 | Glenn Steele Jr Md Phd (Insider) | Sold | $782K |
| Sep 30, 2026 | Glenn Steele Jr Md Phd (Insider) | Bought (not open market) | — |
| Sep 17, 2026 | Michael Schmertzler (Insider) | Sold | $653K |
| Sep 17, 2026 | Michael Schmertzler (Insider) | Sold | $25.7K |
| Sep 16, 2026 | Michael Schmertzler (Insider) | Sold | $472K |
| Sep 16, 2026 | Michael Schmertzler (Insider) | Sold | $199K |
| Sep 10, 2026 | Michael Schmertzler (Insider) | Sold | $673K |
| Sep 9, 2026 | Michael Schmertzler (Insider) | Sold | $639K |
| Sep 9, 2026 | Michael Schmertzler (Insider) | Sold | $39.3K |
| Aug 27, 2026 | Michael Schmertzler (Insider) | Sold | $851K |
| Aug 27, 2026 | Michael Schmertzler (Insider) | Sold | $44.1K |
| Aug 26, 2026 | Michael Schmertzler (Insider) | Sold | $500K |
| Aug 26, 2026 | Michael Schmertzler (Insider) | Sold | $412K |
| Aug 20, 2026 | Michael Schmertzler (Insider) | Sold | $667K |
Who's trading PTCT
- Michael Schmertzler, Insider: sold $6.6M (20 sales), last Oct 14, 2026
- Mark Elliott Boulding, C-suite exec: sold $4.2M (52 sales), last Oct 9, 2026
- Glenn Steele Jr Md Phd, Insider: sold $1.7M (2 sales), last Sep 30, 2026
- Matthew B. Klein, CEO: sold $4.2M (13 sales), last Aug 4, 2026
- Hege Elisabeth Sollie-Zetlmayer, Insider: other filings, last Jul 28, 2026
- Pierre Gravier, CFO: sold $653K (3 sales), last Jul 14, 2026
- Mary L. Smith, Insider: sold $1.4M (2 sales), last Jul 9, 2026
- Neil Gregory Almstead, CTO: sold $22.3M (55 sales), last Jul 9, 2026
- Christine Marie Utter, C-suite exec: sold $1.9M (5 sales), last Jun 17, 2026
- Eric Pauwels, C-suite exec: sold $6.1M (26 sales), last Jun 10, 2026
- Lee Scott Golden, C-suite exec: sold $1.1M (6 sales), last Apr 2, 2026
- Jessica Caroline Chutter, Insider: other filings, last Mar 24, 2026
- Stephanie Okey, Insider: sold $1.5M (3 sales), last Mar 10, 2026
- Emma Reeve, Insider: sold $2.5M (6 sales), last Jan 5, 2026
- Allan Steven Jacobson, Insider: sold $2.1M (10 sales), last Jan 2, 2026
Get free alerts when an insider at PTC Therapeutics, Inc files a new trade →